1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This diagnostic study, while listed as completed, has not yet published its specific findings regarding gastric contents in patients on semaglutide, with the official completion date set for 2025-05-31. However, the f…
Optimizing early T2DM management is crucial for preventing long-term complications and improving patient quality of life. This trial could provide critical evidence for the benefits of aggressive, early combination th…
This study is significant because it provides valuable real-world evidence on Semaglutide's effectiveness, complementing the data from highly controlled clinical trials. Understanding how a drug performs in diverse pa…
This trial is crucial because it seeks to establish tirzepatide as a novel therapeutic option specifically for the reproductive and metabolic challenges faced by women with PCOS. If successful, the findings could sign…
The MAINTAIN study addresses a critical unmet need in obesity management, offering a potential solution to the widespread problem of weight regain after discontinuing GLP-1 RAs. GFMA could provide a durable, non-pharm…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
This study provides compelling evidence that tirzepatide, when added to basal insulin, offers a highly effective strategy for achieving robust glycemic control and significant weight loss in Chinese patients with Type…
This novel evidence strongly suggests that tirzepatide could represent a groundbreaking therapeutic strategy for cocaine use disorder (CUD). Its dual action on GLP-1 and GIP receptors appears to modulate reward pathwa…
This first-of-its-kind case report strongly suggests that Tirzepatide, a dual GLP-1/GIP receptor agonist, may offer a novel and highly effective therapeutic avenue for Lichen Planus. The observed complete remission an…
This real-world data provides crucial insights into the comparative effectiveness of two powerful drug classes for diabetic patients post-ACS. The findings suggest that while both Semaglutide and SGLT2 inhibitors offe…
This study provides compelling evidence that revisional bariatric surgery offers superior long-term weight loss and metabolic comorbidity resolution compared to semaglutide for patients experiencing recurrent weight g…
This study underscores the increasing integration of GLP-1 RAs into the clinical management pathway for patients with severe obesity and related comorbidities who are considering sleep surgery. The observed significan…
The study demonstrated significant improvements across multiple endpoints for the semaglutide group. Semaglutide treatment led to a substantial improvement in heart failure symptoms and physical limitations, with the …
Semaglutide is currently not FDA-approved for Type 1 Diabetes, making this research critical for exploring new therapeutic avenues in a population with significant unmet medical needs. If the trial demonstrates positi…
The potential success of oral semaglutide in effectively managing overweight and obesity would represent a monumental advancement in metabolic medicine, offering a highly convenient, non-injectable treatment option. A…
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
This study holds significant promise as it could identify a new, effective pharmacological treatment for severe forms of obesity like Prader-Willi Syndrome and hypothalamic obesity, which currently have limited therap…
This study is crucial as it addresses a significant unmet need for effective anti-obesity treatments in adult congenital heart disease (ACHD) patients, a population often excluded from major clinical trials. If succes…
This discovery of novel GLP-1 mimotopes represents a significant step forward in the development of new therapeutic agents for type 2 diabetes and obesity. These smaller, potentially more stable, and easier-to-manufac…
The widespread adoption of GLP-1 receptor agonists means plastic surgeons are increasingly encountering patients with significant, rapid weight loss, necessitating a paradigm shift in surgical planning. This review pr…
This study provides valuable real-world evidence, reinforcing Semaglutide's efficacy not only in achieving substantial weight loss but also in improving critical metabolic parameters and, importantly, the overall heal…
The findings from this study are incredibly significant as they underscore the potential of Semaglutide as a highly effective treatment option for adolescent obesity, a condition with limited pharmacological solutions…
This comprehensive meta-analysis provides strong evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior glycemic control and weight loss benefits compared to Dulaglutide, a selective GLP-1 recep…
This study provides valuable real-world insights into the comparative safety profiles of tirzepatide, semaglutide, and liraglutide, which can complement findings from controlled clinical trials. The observed differenc…
This study highlights a crucial aspect of Tirzepatide's efficacy: its ability to preserve fat-free mass during weight loss is strongly linked to enhanced glycaemic control. This finding suggests that Tirzepatide offer…
This study provides compelling evidence that GLP-1 RA therapy is a highly effective, less invasive treatment option for Idiopathic Intracranial Hypertension, offering comparable visual benefits to bariatric surgery. T…
This review provides crucial, evidence-based practical guidance for clinicians navigating the complex, often challenging, management of patients with concurrent CKD and T2D. By synthesizing the latest research and off…
This study provides compelling evidence that combining GLP-1RA and SGLT2i therapies offers a powerful and potentially synergistic strategy to mitigate liver fibrosis progression in patients with MASLD and Type 2 Diabe…
This study provides compelling evidence that semaglutide is highly effective in reversing advanced MASH pathology, including significant liver fibrosis, in a robust and clinically relevant animal model. The observed i…
The findings summarized in this review suggest that PentaPeptide-5 and similar multi-receptor agonists represent a significant advancement in the treatment of obesity and type 2 diabetes. By targeting multiple metabol…
The successful demonstration of semaglutide's safety and tolerability in CFRD patients would be a significant step forward, potentially offering a novel therapeutic avenue beyond insulin. If proven safe and effective …
This two-year study is crucial for understanding the long-term effectiveness and safety of Semaglutide as a treatment for overweight and obesity. If the results demonstrate sustained weight loss and a favorable safety…
This multi-national trial is crucial for understanding the comparative effectiveness of two prominent classes of Type 2 Diabetes medications when added to standard metformin therapy. The findings, once published, will…
Understanding how liver function affects oral semaglutide's pharmacokinetics is crucial for dose adjustments and patient safety, especially given the widespread use of GLP-1 receptor agonists for type 2 diabetes. The …
This study holds significant promise for addressing a critical unmet medical need: effective treatment for early-onset, treatment-resistant obesity in young adults. If successful, the RESETTLE Study could establish se…
This study holds significant promise for improving the health outcomes of people living with HIV who struggle with obesity and chronic inflammation. If successful, the findings could establish tirzepatide as a valuabl…
The discontinuation of GLP-1 agonists often leads to weight regain and a return of metabolic challenges, including elevated triglycerides, which are risk factors for cardiovascular disease. If RDX-002 proves effective…